Why the study?
Does trastuzumab increase the risk of heart failure and/or cardiomyopathy in Taiwanese women with breast cancer?
Population
23,006 Taiwanese women with incident breast cancer receiving chemotherapy, mean age 50.99 years.
Comparison
Trastuzumab vs Nonusers of trastuzumab
Design
Cohort
Follow-up
median 5.29 years
Authors
Loading...
Trastuzumab-related HF/CM risk in Asian women remains incompletely defined; leaves open need for ethnicity-specific monitoring trials.
Does trastuzumab increase the risk of heart failure and/or cardiomyopathy in Taiwanese women with breast cancer?
In Taiwanese women with breast cancer, trastuzumab is associated with an 86% increased relative risk of heart failure or cardiomyopathy at 1 year, though the absolute incidence is lower than reported in Western populations.
Chien et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: